Voyager Therapeutics

Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. The company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics was launched in 2014 with funding from leading life sciences investor Third Rock Ventures and is headquartered in Cambridge, Mass.
Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2014
Size (employees)
52 (est)
Voyager Therapeutics was founded in 2014 and is headquartered in Cambridge, US

Key People at Voyager Therapeutics

Mark Kay

Mark Kay

Founder
Phillip D. Zamore

Phillip D. Zamore

Founder
Guangping Gao

Guangping Gao

Founder
Krystof Bankiewicz

Krystof Bankiewicz

Founder
Jeff Goater

Jeff Goater

Vice President of Business Development
James Geraghty

James Geraghty

Interim Chief Business Officer

Voyager Therapeutics Office Locations

Voyager Therapeutics has an office in Cambridge
Cambridge, US (HQ)
75 Sidney St

Voyager Therapeutics Data and Metrics

Voyager Therapeutics Financial Metrics

Voyager Therapeutics's revenue was reported to be $14.2 m in FY, 2016 which is a 18% decrease from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

14.2 m

Revenue growth (FY, 2015 - FY, 2016), %

(18%)

Net income (FY, 2016)

(40.2 m)

EBITDA (FY, 2016)

(41.3 m)

Market capitalization (23-May-2017)

251.3 m

Closing share price (23-May-2017)

9.2
Voyager Therapeutics's current market capitalization is $251.3 m.
Numbers are in $, USDFY, 2015FY, 2016

Revenue

17.3 m14.2 m

Revenue growth, %

(18%)

EBITDA

(20.5 m)(41.3 m)

EBITDA margin, %

(118%)(290%)

Net Income

(3.8 m)(40.2 m)
Numbers are in $, USDFY, 2015FY, 2016

Current Assets

195.9 m178.8 m

PP&E

3.2 m7.9 m

Total Assets

229.5 m189.6 m

Accounts Payable

612 k550 k

Current Liabilities

23.9 m13.8 m

Additional Paid-in Capital

219.1 m226 m

Retained Earnings

(49.8 m)(90 m)
Numbers are in $, USDFY, 2015FY, 2016

Net Income

(3.8 m)(40.2 m)

Depreciation and Amortization

600 k612 k

Inventories

(234 k)(847 k)

Accounts Payable

950 k(62 k)

Cash From Operating Activities

(2.7 m)(42.5 m)

Purchases of PP&E

(1 m)(5 m)

Cash From Investing Activities

(194.8 m)47.3 m

Cash From Financing Activities

2.9 m514 k
Numbers are in $, USDY, 2016

Revenue/Employee

273.5 k

Voyager Therapeutics Operating Metrics

FY, 2016

Patent Applications

28

Patents Issued

157

Voyager Therapeutics Market Value History

Voyager Therapeutics Company Life and Culture

You may also be interested in